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n INTRODUCTION
Lymphadenitis and abscess formation arethe most common side effects of BacilleCalmette-Guerin (BCG) vaccination. The
incidence of BCG lymphadenitis differs
worldwide, ranging from 0.5% to 23%. The
likelihood of lymphadenitis is higher when
BCG vaccination is performed at a lower age
[1-12]. Tuberculosis (TB) remains a global
public health problem and is considered a vi-
tal health issue in countries with low income,
poor nutrition, and unmodified social stan-
dards [4]. 
The BCG vaccine, which is used to prevent
TB, has been made available to the public
since 1921. The World Health Organization
(WHO) offers BCG vaccination as part of the
Global Expanded Program of Immunization
(EPI) in developing countries [5, 13]. The BCG
vaccine is a live attenuated vaccine that was
developed from a strain of Mycobacterium bo-
vis [5]. Its efficacy has been reported to vary
from 50% to 90%[12, 14, 15]. Although its effi-
cacy is not considerable, some studies report
that the BCG vaccine can prevent miliary TB
and tuberculous meningitis [16].
After intradermal injection of the TB vaccine,
BCG begins to proliferate at the injection site
and then infiltrates the regional lymph nodes
through the lymphatic system. Finally, it is car-
ried away by the blood and forms small foci of
infection in various organs. This sequence of
events is the normal BCG reaction, which re-
sults in successful BCG vaccination [17].
Although BCG vaccination is safe, it can occa-
sionally cause lymphadenitis, localized ulcer-
ation, osteomyelitis, lipoid reactions, eczema
vaccinatum, hypertrophic scars, keloid forma-
tion, disseminated infection, and death [4, 5,
14, 15, 18-21]. 
Two forms of BCG lymphadenitis may occur
after TB vaccination. The first is a simple, non-
suppurative lymphadenitis, which resolves
spontaneously in a few weeks. The second
form is a suppurative lymphadenitis, which is
characterized by a fluctuant swelling, erythe-
ma, and edema of the skin [4, 5].
Opinions on how to treat the acute symptoms
vary widely and include many types of inter-
ventions such as surgical drainage, antibi-
otics, and even anti-TB treatments. The use-
fulness of these treatments is controversial [5,
15, 18]. The present study investigated the ef-
fect of oral cephalexin on patients who devel-
oped BCG lymphadenitis after anti-TB vacci-
nation.
n PATIENTS AND METHODS
The study involved 40 children (24 boys and
16 girls) who were referred to Qazvin Chil-
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dren’s Hospital, Qazvin, Iran, for the treat-
ment of non-suppurative BCG lymphadenitis
between December 2008 and the end of Sep-
tember 2009. Qazvin Children’s Hospital is a
referral center in which about 10,000 children
are hospitalized in a year, and 100,000 chil-
dren are treated in its outpatient clinics every
year. It covers not only patients from Qazvin
province but also some patients from neigh-
boring provinces. The diagnostic criteria for
BCG lymphadenitis consisted of ipsilateral ax-
illary, supraclavicular, or cervical lym-
phadenitis, with the affected nodes measuring
at least 0.5 cm wide, and the absence of any
detectable cause other than BCG vaccination
administered up to 6 months before. The in-
clusion criteria for this study were: 
1) age below 36 months;
2) BCG lymphadenitis;
3) no other diseases, and
4) no history of any treatment prior to admis-
sion [1]. 
In total, 40 children who met the above crite-
ria were included in the study after obtaining
the approval of the hospital ethics committee
and consent from the children’s parents.
All patients were examined by a pediatric in-
fectious disease specialist. The size of the
lymph nodes and the BCG scar was noted.
The largest transverse diameter of the affected
lymph nodes was recorded as the lymph node
size. All patients had received 0.05 ml (0.05
mg) BCG vaccine (Pasteur Institute, Tehran,
Iran) intradermally in the distal third of the
deltoid muscle of the right arm [1, 4].
To our knowledge, the susceptibility of My-
cobacterium bovis to cephalexin has not been
evaluated. This antibiotic was selected be-
cause (1) it is active against gram positive or-
ganisms such as Staphylococcus aureus, which
may complicate BCG lymphadenitis, and (2) a
literature review indicated that most staphy-
lococcal infections are susceptible to cephalex-
in. Thus, this antibiotic would treat superim-
posed bacterial infection, which is likely to
complicate BCG lymphadenitis. Patients were
randomly divided into two groups A and B.
Patients in group A (n = 20) did not receive
any treatment and were considered as the
control group. Group B patients received oral
cephalexin (50 mg/kg/day in four doses) for
10 days. If the affected lymph nodes were
fluctuant in the follow-up period, fine needle
aspiration (FNA) was performed [1]. To pre-
vent sinus formation, FNA was performed by
inserting the needle 2 cm away from the pe-
riphery of the lymph nodes [1]. 
All patients were called to the hospital for re-
examination 10 days after the last cephalexin
dose was administrated. During re-examina-
tion, each patient underwent a complete phys-
ical examination, and the lymph node size
and local symptoms such as fluctuation,
warmth, and erythema as well as systemic
symptoms were noted. 
Serial examinations continued until recovery
from lymphadenitis, which was defined as a
decrease in lymph node size to <0.5 cm and
the absence of local symptoms such as sinus
formation and residual ulceration, without
any systemic symptoms or radiographic
changes indicative of tuberculosis. 
Data from the two groups were compared by
the unpaired student T test. The alpha coeffi-
cient was taken as 0.05. 
n RESULTS
In all 40 patients who met the inclusion crite-
ria, the findings of clinical examination were
normal, except for lymphadenitis. The mean
age at onset of lymphadenitis in the patient
(A) and control (B) groups was 5.5±2.87 and
6.07±3.35 months, respectively (Table 1). 
The axillary lymph nodes were involved in 38
patients (19 each in the intervention and con-
trol groups), and the supraclavicular lymph
nodes were involved in 2 patients (one each in
the intervention and control groups).
A polymerase chain reaction (PCR) test was
performed in both groups and was positive
for TB bacilli. FNA had to be performed in 3
patients in the control group and 2 patients in
Table 1 - Clinical findings in both groups.
Number Mean age at onset of lymphadenitis Lymphadenitis size
(months) <1 cm 1-3 cm <3 cm
No treatment 20 6.07±3.35 7 9 4
Cephalexin 20 5.5±2.87 7 10 3
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the intervention group because of the emer-
gence of lymphadenitis complications.
The average recovery period in the interven-
tion group (16.1±6.5 weeks) was similar to
that in the control group (15.8±5.7 weeks).
None of the patients experienced side effects
of cephalexin during the study.
n DISCUSSION
After intradermal injection of the BCG vac-
cine, the vaccine intervention spreads through
the lymphatic system to the local lymph
nodes and induces immunity against primary
tuberculosis infection. However, the level of
immunity provided against the various forms
of tuberculosis differs [5, 6, 22]. BCG vaccina-
tion leads to the formation of the classic pri-
mary complex, which consists of a cutaneous
nodule at the vaccination site and swelling of
the local lymph nodes. This phenomenon is
usually self-limiting and requires no treat-
ment [1, 5]. However, a small percentage of
these patients develop an excessive reaction
that eventually progress to suppurative lym-
phadenitis [1, 5, 22]. BCG lymphadenitis usu-
ally occurs 2 to 8 weeks after vaccination;
however, some studies have reported the
emergence of BCG lymphadenitis after 8
months [5, 14, 15, 23, 24]. Factors influencing
the incidence of BCG lymphadenitis include
vaccination technique, vaccine type, age,
dose, concentration, potency, viability, im-
munogenicity, prior exposure to mycobacteri-
al antigen, and duration of vaccine storage [1,
5, 14, 15, 23-26]. Vaccination at a lower age is
associated with a higher possibility of subse-
quent BCG lymphadenitis. Studies on chil-
dren with BCG lymphadenitis have shown
that malnutrition and immune deficiency do
not considerably affect the development of
BCG lymphadenitis [1,5].
An epidemic of BCG lymphadenitis has been
reported in many countries, including Iran [5,
14, 27-33]. Analysis of these epidemics has
shown that BCG lymphadenitis constitutes a
strong response to potent, highly safe vac-
cines. BCG vaccines are produced in various
laboratories, and thus, the BCG strains used
differ slightly with regard to phenotype and
genotype [5, 14, 21]. The vaccines prepared
from these strains probably differ in terms of
their side effects and protective effects [14]. 
Treatment strategies for BCG lymphadenitis
range from no intervention to various medical
and surgical treatments [17, 28, 34-40]. Ery-
thromycin was the first drug reported to be ef-
fective against ulcers and abscesses that form
after BCG vaccination and to accelerate the re-
covery process [41]. However, randomized
controlled trials have found that ery-
thromycin is ineffective for the treatment of
BCG lymphadenitis [1, 42, 43]. The findings of
these trials are probably correct because the
minimum inhibitory concentration (MIC) of
erythromycin against tuberculous bacilli is
much higher than blood and tissue concentra-
tions after oral erythromycin administration
[41]. 
Oguz and Caglayan found that erythromycin
may have some beneficial effect on lym-
phadenitis that occurs soon after BCG vacci-
nation, but erythromycin is not routinely pre-
scribed for the treatment of BCG lymphadeni-
tis [40, 42]. Kuyucu et al. found that the mean
recovery time in patients treated by aspiration
and oral erythromycin administration was
identical to that in patients who received no
treatment [1]. Some authors have reported
that because of the effect of erythromycin on
gram-positive cocci, the administration of this
drug tends to complicate BCG lymphadenitis
[43]. 
Furthermore, Baki et al. showed that while
isoniazid (INH) administration does not de-
crease disease duration, surgical intervention
effectively shortens the duration of BCG lym-
phadenitis [17]. Since BCG bacilli are suscep-
tible to INH, the ineffectiveness of this drug in
the treatment of BCG lymphadenitis is sur-
prising and intriguing [6]. One possible expla-
nation could be an underlying hypersensitivi-
ty response to BCG proteins as well as to INH
and other anti-TB drugs [37]. Another expla-
nation is that the BCG bacillus plays no role in
the formation of BCG lymphadenitis; samples
from affected lymph nodes show low positiv-
ity for bacilli on culture, and few acid-fast
bacilli (AFB) are present in smears prepared
from such lymph nodes [27, 43]. 
During treatment of tuberculous lymphadeni-
tis, hypersensitivity responses, characterized
by enlargement, fluctuant swelling, and sup-
puration of the lymph nodes, can occur, and
these responses are similar to the clinical
course of BCG lymphadenitis treated with
INH [44]. 
In a study conducted by Bhandari on 40 chil-
dren, recovery from BCG lymphadenitis was
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faster after surgical intervention than after
drug treatment alone [45]. Furthermore, in
that study, treatment with INH or strepto-
mycin or both was administered to 26 patients
with BCG lymphadenitis, but none of the
treatments shortened the recovery period [45]. 
Other authors found that AFB were detected
in more than a third of the patients in their
study; however, Bhandari reported that AFB
were not detected on direct smear in any of
their study patients [45-47]. 
In our study, PCR tests demonstrated the
presence of TB bacilli in all patients. In the
study by Bhandari, as in many other studies,
recovery from non-suppurative adenitis oc-
curred within 12-15 weeks. Bhandari did not
find a statistically significant reduction in the
time until recovery from BCG lymphadenitis
by various treatment regimens such as ery-
thromycin, INH, INH plus erythromycin, and
placebo (P>0.05) [45]. 
In the current study, treatment with oral
cephalexin did not hasten recovery from BCG
lymphadenitis (P>0.05). Mehta et al. have
shown that anti-TB drugs are useful for the
treatment of BCG lymphadenitis [48]. Howev-
er, Bhandari et al. reported that anti-TB drugs
have no therapeutic effect on BCG lymphadeni-
tis [45]. In our study, we found that cephalexin
has no effect on BCG lymphadenitis.
n CONCLUSION
Our study and recent research show that non-
suppurative lymphadenitis after BCG vacci-
nation is a benign condition that usually im-
proves spontaneously within 3 to 4 months. In
such cases, it is sufficient to simply reassure
the parents. If lymphadenitis is purulent, the
most appropriate treatment is surgical
drainage of the lymph nodes and antibiotic
therapy. 
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Lymphadenitis and abscess formation are the
most common side effects of vaccination with
Bacille Calmette Guerin (BCG). 
The lower the child’s age at the time of vaccina-
tion, the higher the incidence of BCG lym-
phadenitis tends to be. Although various thera-
peutic approaches are in use for the treatment of
BCG lymphadenitis, there is no consensus on
which of them is optimal. 
This study aimed to determine whether oral
cephalexin treatment hastens recovery from
BCG lymphadenitis. 
The study involved 40 children (24 boys and 16
girls) with BCG lymphadenitis who were re-
ferred to Qazvin Children’s Hospital, Qazvin
University of Medical Sciences between Decem-
ber 2008 and the end of September 2009. The pa-
tients were randomly assigned to two groups of
20 patients each (12 boys and 8 girls in each
group): group A patients did not receive any
treatment and served as controls, and group B
patients were treated with 50 mg/kg/day
cephalexin syrup, administered in four doses,
for 10 days. 
In all patients, clinical examination was normal,
except for lymphadenitis. In all patients, BCG
vaccination had been performed at birth, and
polymerase chain reaction tests were positive
for tuberculous bacilli. The recovery period and
requirement of fine needle aspiration did not
significantly differ between the two groups (P >
0.05). This study showed that treatment with
cephalexin does not hasten recovery from BCG
lymphadenitis.
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La linfadenite e la comparsa di ascessi sono gli effet-
ti collaterali che si verificano con maggiore frequen-
za in seguito alla vaccinazione con i bacilli di Cal-
mette Guerin (BCG). L’incidenza della linfadenite da
BCG è tanto maggiore quanto minore è l’età del bam-
bino al momento della vaccinazione. Per il tratta-
mento della linfadenite da BCG, sono in uso diversi
approcci terapeutici ma non vi è un consenso unani-
me su quale di essi sia da ritenere ottimale.
Questo studio è stato intrapreso al fine di determina-
re se il trattamento con cefalexina per via orale sia in
grado di accelerare il processo di guarigione dalla lin-
fadenite da BCG. 
Nello studio sono stati arruolati 40 bambini (24 ma-
schi e 16 femmine) affetti da linfadenite da BCG in-
viati al Qazvin Children’s Hospital, Qazvin Univer-
sity of Medical Sciences nel periodo dicembre 2008 -
fine settembre 2009. 
I pazienti sono stati randomizzati in due gruppi di
20 pazienti ciascuno (12 maschi e 8 femmine in cia-
scun gruppo): i pazienti del gruppo A non hanno ri-
cevuto nessun trattamento e sono stati utilizzati co-
me controlli mentre i pazienti del gruppo B sono sta-
ti trattati con 50 mg/kg/die di cefalexina sciroppo,
somministrato in quattro dosi per 10 giorni. In tutti
i pazienti, l’esame clinico è risultato normale, fatta
eccezione per la presenza di linfadenite. In tutti i pa-
zienti, la vaccinazione con BCG era stata effettuata
alla nascita e i test con la polymerase chain reac-
tion sono risultati positivi per la presenza di bacilli
tubercolari. Il periodo di guarigione e la necessità di
ricorrere ad aspirazione con ago sottile non differiva-
no tra i due gruppi in maniera significativa (P >
0,05). Il nostro studio ha indicato che il trattamento
con cefalexina non accelera la guarigione della linfa-
denite da BCG.
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